VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SHPH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SHPHShuttle Pharmaceuticals Holdings, Inc.
$3.26$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SHPH logoShuttle Pharmaceuticals Holdings, Inc.(SHPH)Earnings, Financials & Key Ratios

SHPH•NASDAQ
$3.26
Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTherapy-focused branded biopharma
AboutShuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.Show more
  • Revenue$0
  • EBITDA-$12M-51.2%
  • Net Income-$12M-28.2%
  • EPS (Diluted)-71.60+99.2%
  • ROE-791.04%-106.1%

SHPH Price & Volume

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Threaten Immediate Liquidity Solvency

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk

Key Thesis Takeaways

  • Shuttle Pharmaceuticals faces an existential financial challenge as its pre-revenue clinical-stage model continues to generate significant quarterly operating losses, peaking at $3.9M in 2025Q2.
  • The company's reliance on external financing to fund R&D, which reached $1.6M in 2025Q1, has led to severe equity erosion with accumulated deficits totaling $48.5M as of 2026Q1.
  • Investors should monitor the firm's ability to secure non-dilutive capital, as the current cash position of $334,005 suggests an imminent risk of insolvency.

Verdict Logic

the company's cash reserves of $334,005 against a history of multi-million dollar quarterly burn rates indicate a critical liquidity shortfall that necessitates immediate and likely dilutive capital intervention.

SHPH Growth Metrics

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-3.39%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-224.06%

Return on Capital

10 Years-650.64%
5 Years-279.14%
3 Years-346.62%
Last Year-684.56%

SHPH Recent Earnings

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
Q2 2026Latest
May 15, 2026
Metric
Actual
Est
EPS
$0.43
—
Rev
—
—
Q2 2026
Apr 1, 2026
Metric
Actual
Est
EPS
$1.29
—
Rev
—
—
Q4 2025
Nov 13, 2025
Metric
Actual
Est
EPS
$1.05
—
Rev
—
—
Q3 2025
Aug 12, 2025
Metric
Actual
Est
EPS
$3.29
—
Rev
—
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 15, 2026
$0.43
—
Q2 2026Apr 1, 2026
$1.29
—
Q4 2025Nov 13, 2025
$1.05
—
Q3 2025Aug 12, 2025
$3.29
—
Based on last 12 quarters of dataView full earnings history →

Latest SHPH News

Recent stock market news and headlines for Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Newsfile Corp·Jun 26, 2026
United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site

United Dogecoin looks to have its miners operational within approximately 60 days, leveraging low-cost, renewable energy, on its path to being the market's largest Dogecoin miner by hashrate Gaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle"), has completed two significant milestones on its projected path to market scale and operational excellence. United Dogecoin has purchased its first fleet of ElphaPex DG1+ mining units, which the Company believes are among the most powerful and efficient Dogecoin miners available.

Newsfile Corp·Jun 25, 2026
United Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting

United Dogecoin shares insights on its digital infrastructure strategy, aimed at expanding revenue opportunities and supporting long-term shareholder value creation. Gaithersburg, Maryland--(Newsfile Corp. - June 25, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining and digital infrastructure company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle"), has initiated an evaluation of proprietary data centre and power generation opportunities designed to support long-term DOGE mining operations and future AI infrastructure workloads.

Peers Comparison

Key metrics vs top competitors for Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SHPH logoSHPHShuttle Pharmaceuticals Holdings, Inc.Current
$3.26$1.64M-0.05——-791.04%—
SENS logoSENSSenseonics Holdings, Inc.
$5.33$222.76M-3.2156.89%-214.16%-130%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—
AGEN logoAGENAgenus Inc.
$3.50$145.75M-1029.4110.37%52.16%——
ATNM logoATNMActinium Pharmaceuticals, Inc.
$1.03$32.32M-0.95—-26078.89%-218.67%—
CELC logoCELCCelcuity Inc.
$115.72$5.64B-30.61——-244.61%—

Compare SHPH vs Peers

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SENS

Most directly comparable listed peer for SHPH.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare SHPH against a more recognizable public peer.

Peer Set

Compare Top 5

vs SENS, NVCR, AGEN, ATNM

SHPH SEC Filings & Documents

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 27, 2026·SEC

Material company update

May 7, 2026·SEC

Material company update

May 1, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 31, 2026·SEC

FY 2025

Feb 26, 2025·SEC

10-Q Quarterly Reports

5
FY 2026

May 15, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 13, 2025·SEC

Get notified when SHPH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SHPH Frequently Asked Questions

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is SHPH profitable?

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $10.8M for fiscal year 2025.

Dividend & Returns
What is SHPH's return on equity?

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has a return on equity (ROE) of -791.0%. Negative ROE indicates the company is unprofitable.

What is Shuttle Pharmaceuticals Holdings, Inc.'s free cash flow?

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had negative free cash flow of $9.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in SHPH back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →